NYU Langone Health

The volume of $100m-plus venture capital mega-rounds continues to build throughout 2023 after a slow start, but a wider look at the biopharmaceutical VC landscape illustrates the valley of death that

Raising venture capital or launching an initial public offering in 2023 is nowhere near as easy as it was in the record-breaking VC funding and IPO days of 2020 and 2021, after a rough 2022 when fundr

Lysogene Licenses Gene Therapy Candidate From Yeda Research Advancing a collaboration inked in July 2020, gene therapy specialist Lysogene SA said on 12 April that it is taking its option to license

Bristol Myers Squibb Company is under pressure to bring new drugs to market before several of its current blockbuster products face generic and biosimilar competition. But in addition to a suite of l